Search

Formoterol

Formoterol is an inhaled beta₂-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. … [L11256] It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting muscarinic antagonists.

Dimethicone

It is used in a number of health and beauty products including hair care products such as shampoo, conditioner, leave-in conditioner, and de-tangling products. … On skin, it is also observed to have moisturizing actions [L1771, L1773].

Oxymetazoline

[L15057] In July 2020, the FDA approved the use of an ophthalmic formulation of oxymetazoline (Upneeq) in adults with acquired blepharoptosis, or ptosis, making it the first FDA-approved medical treatment … [A215587, L15092] In dentistry, oxymetazoline and tetracaine combination intranasal spray (Kovanaze) is used for regional anesthesia during dental procedures in children and adults.

Camphor

Camphor is a bicyclic monoterpene ketone found widely in plants, especially _Cinnamomum camphora_. It is used topically as a skin antipruritic and as an anti-infective agent. … It appears in the list of drug products withdrawn or removed from the market for safety or effectiveness.

Terbinafine

[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. … [A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064]

MG-4101

Bendamustine

Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. … Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).

Venlafaxine

[A252065] Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. … It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).

Pramipexole

It was first approved by the FDA in 1997 [L5882]. … The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016 [A176861].

Oxybutynin

[A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990] … Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.